Company intelligence / Profile preview
Atterx Biotherapeutics
Madison, Wisconsin, United Statesatterx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Atterx is developing novel products to prevent and treat antibiotic-resistant bacterial infections. Their lead product C-1205 uses bacterial interference technology to prevent catheter-associated UTIs and has received FDA approval for a Phase I trial. Their GN-4474 product is in preclinical development for gram-negative bacterial infections.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Bacterial interference technologyBacterial conjugation
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Atterx Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atterx Biotherapeutics.